TY - JOUR
T1 - Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models
AU - Volgin, Andrey D.
AU - Yakovlev, Oleg A.
AU - Demin, Konstantin A.
AU - Alekseeva, Polina A.
AU - Kyzar, Evan J.
AU - Collins, Christopher
AU - Nichols, David E.
AU - Kalueff, Allan V.
N1 - Publisher Copyright:
© 2018 American Chemical Society.
PY - 2019/1/16
Y1 - 2019/1/16
N2 - Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as "deliriants". Although atropine and scopolamine are relatively well-studied drugs in cholinergic physiology, deliriants represent the least-studied class of hallucinogens in terms of their behavioral and neurological phenotypes. As such, novel approaches and new model organisms are needed to investigate the CNS effects of these compounds. Here, we comprehensively evaluate the preclinical effects of deliriant hallucinogens in various animal models, their mechanisms of action, and potential interplay with other signaling pathways. We also parallel experimental and clinical findings on deliriant agents and outline future directions of translational research in this field.
AB - Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as "deliriants". Although atropine and scopolamine are relatively well-studied drugs in cholinergic physiology, deliriants represent the least-studied class of hallucinogens in terms of their behavioral and neurological phenotypes. As such, novel approaches and new model organisms are needed to investigate the CNS effects of these compounds. Here, we comprehensively evaluate the preclinical effects of deliriant hallucinogens in various animal models, their mechanisms of action, and potential interplay with other signaling pathways. We also parallel experimental and clinical findings on deliriant agents and outline future directions of translational research in this field.
KW - antimuscarinic agents
KW - deliriants
KW - Hallucinogens
KW - rodents
KW - zebrafish
UR - http://www.scopus.com/inward/record.url?scp=85055153870&partnerID=8YFLogxK
U2 - 10.1021/acschemneuro.8b00433
DO - 10.1021/acschemneuro.8b00433
M3 - Review article
C2 - 30252437
AN - SCOPUS:85055153870
SN - 1948-7193
VL - 10
SP - 143
EP - 154
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 1
ER -